51. Scleroderma Clinical trials / Disease details
Clinical trials : 523 / Drugs : 608 - (DrugBank : 156) / Drug target genes : 114 - Drug target pathways : 215
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05000216 (ClinicalTrials.gov) | August 13, 2021 | 6/8/2021 | COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders | Booster Effects With Autoimmune Treatments in Patients With Poor Response to Initial COVID-19 Vaccine (ACV01) | Rheumatoid Arthritis;Systemic Lupus Erythematosus (SLE);Pemphigus Vulgaris;Multiple Sclerosis;Systemic Sclerosis (SSc) | Biological: Moderna mRNA-1273;Biological: BNT162b2;Biological: Ad26.COV2.S;Drug: IS (MMF or MPA);Drug: IS (MTX);Biological: IS (B cell depletion therapy) | National Institute of Allergy and Infectious Diseases (NIAID) | Autoimmunity Centers of Excellence;Rho Federal Systems Division, Inc. | Recruiting | 18 Years | N/A | All | 600 | Phase 2 | United States |
| 2 | NCT04244916 (ClinicalTrials.gov) | May 25, 2020 | 6/1/2020 | MPA AUC Monitoring in Patients Receiving MMF for Diffuse Cutaneous or Pulmonary Involvement in Systemic Sclerosis | Prospective Study to Investigate the Relevance of Monitoring Area Under the Curve of Mycophenolic Acid in Patients Receiving Mycophenolate Mofetil to Treat a Diffuse Cutaneous or a Pulmonary Involvement of Systemic Sclerosis | Systemic Sclerosis | Biological: AUC of MPA measure | Assistance Publique - Hôpitaux de Paris | NULL | Recruiting | 18 Years | N/A | All | 50 | France | |
| 3 | NCT03678987 (ClinicalTrials.gov) | September 13, 2018 | 13/9/2018 | Mycophenolate Mofetil Pharmacokinetics in Systemic Sclerosis | Mycophenolate Mofetil in Systemic Sclerosis: A Phase 1 Pharmacokinetic Study of Orally Ingested Mycophenolate Mofetil Tablets in Patients Suffering From Systemic Sclerosis | Systemic Sclerosis;Gastrointestinal Complication | Diagnostic Test: P-MPA concentration;Drug: mycophenolic acid | Region Skane | NULL | Completed | 18 Years | N/A | All | 35 | Phase 1 | Sweden |
| 4 | NCT03644225 (ClinicalTrials.gov) | June 11, 2018 | 4/5/2018 | Suction Based Characterization of Healthy and Diseased Skin | Mechanical Characterization of Healthy and Diseased Skin With Suction Based Assessment of Skin Deformability | Systemic Sclerosis | Device: Measurment with Aspirational Medical Device;Device: Measurment with Cutometer MPA 580 | Oliver Distler | Swiss Federal Institute of Technology | Completed | 18 Years | N/A | All | 67 | N/A | Switzerland |